Abstract: The present disclosure provides, inter alia, pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. In certain embodiments, the pharmaceutical compositions contain nonabsorbable compositions and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons, the conjugate base of a strong acid and/or a strong acid from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human. In certain embodiments, compositions for and methods of improving the quality of life and/or physical function score of such patients are also provided. In certain embodiments, compositions for and methods of slowing the progression of kidney disease in such patients are also provided.

Abstract: The present disclosure provides, inter alia, pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. In certain embodiments, the pharmaceutical compositions contain nonabsorbable compositions and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons, the conjugate base of a strong acid and/or a strong acid from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human. In certain embodiments, compositions for and methods of improving the quality of life and/or physical function score of such patients are also provided. In certain embodiments, compositions for and methods of slowing the progression of kidney disease in such patients are also provided.

Abstract: An apparatus and method particularly useful in treatments and therapies directed at the kidneys such as the prevention of radiocontrast nephropathy (RCN) arising from diagnostic procedures using iodinated contrast materials. A series of treatment schemes are provided based upon local therapeutic agent delivery to the kidneys that can be used as a prophylactic treatment for patients undergoing interventional procedures that have been identified as being at an elevated risk for developing RCN as well as for low risk patients. The methods may include pre-exposure and post contrast exposure treatments alone or in combination with the local delivery of therapeutic agents to the kidneys. Among the agents identified for such treatments are normal saline and the vasodilators papaverine and fenoldopam mesylate and appropriate dosing is provided.

Abstract: Bifurcated delivery assemblies provide bilateral access to first and second branch lumens extending from a main body space or lumen in a patient. One or more interventional devices are combined with the delivery assemblies for delivery s into one or both of the branch lumens. Bilateral renal stenting or embolic protection procedures are performed using the combination delivery/interventional device assemblies. Fluids may also be injected or aspirated from the assemblies. A bifurcated catheter has a first fluid port located on one bifurcation branch, a second fluid port located on a second branch of the bifurcation, and a third fluid port positioned so as to be located within a vena cava when the first and second ports are positioned bilaterally within first and second renal veins.

Abstract: Transdermal administration of fenoldopam, both the racemic mixture and the active R-fenoldopam enantiomer, is described. Also described are transdermal patches for therapeutically effective transdermal administration of racemic fenoldopam and its active R-fenoldopam enantiomer to a subject in need of treatment for impaired renal function or hypertension.